Anixa Biosciences (ANIX) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed Anixa Biosciences (ANIX) over the past year, losing 28.7% versus a loss of 34.9%. Over five years, ANIX leads with a -38.5% price change compared with -86.8% for UNCY. Anixa Biosciences is the larger company by market cap ($92.8 million vs $92.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | UNCY |
|---|---|---|
| Share price | $2.67 | $3.36 |
| Market cap | $92.82M | $92.04M |
| 1-day change | -3.96% | -6.41% |
| YTD return | -14.42% | -41.77% |
| 1-year return | -34.88% | -28.66% |
| 5-year return | -38.48% | -86.77% |
| Forward P/E | — | 1.99 |
| EPS (TTM) | $-0.32 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-10.93M | $-26.55M |
| 52-week high | $5.46 | $8.74 |
| 52-week low | $2.32 | $3.35 |
| Distance from 52-week high | -51.10% | -61.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +265.17% | +745.24% |
| Average volume | 296.48K | 845.87K |
| Shares outstanding | 34.76M | 27.39M |
| Employees | 4 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ANIX vs UNCY FAQ
Which is bigger, Anixa Biosciences or Unicycive Therapeutics?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $92.82M compared with $92.04M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, ANIX or UNCY?
UNCY returned -28.66% over the past 12 months, compared with -34.88% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.